Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2005 1
2007 1
2008 1
2009 3
2010 1
2011 1
2012 1
2014 1
2016 2
2017 1
2018 1
2019 5
2021 2
2022 4
2023 5
2024 4
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.
Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Lecuru F, Ferron G, Brigand C, Berton D, Gladieff L, Joly F, Ray-Coquard I, Durand-Fontanier S, Liberale G, Pocard M, Georgeac C, Gouy S, Guilloit JM, Guyon F, Costan C, Rousselet JM, de Guerké L, Bakrin N, Brument E, Martin E, Asselain B, Campion L, Glehen O; UNICANCER/CHIPOR Investigators. Classe JM, et al. Among authors: gladieff l. Lancet Oncol. 2024 Dec;25(12):1551-1562. doi: 10.1016/S1470-2045(24)00531-X. Epub 2024 Nov 14. Lancet Oncol. 2024. PMID: 39549720 Clinical Trial.
After six cycles of platinum-based chemotherapy (and optional bevacizumab), patients amenable to complete cytoreductive surgery were randomly assigned centrally in a 1:1 ratio, using a web-based system and a minimisation procedure, during surgery to receive HIPEC (cisplatin 75 mg …
After six cycles of platinum-based chemotherapy (and optional bevacizumab), patients amenable to complete cytoreductive surgery were randoml …
Dostarlimab and niraparib in primary advanced ovarian cancer.
Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, Montestruc F, Redondo A, Mirza MR, Cibula D, Ciuleanu TE, Gilbert L, Eitan R, Zagouri F, Pignata S, Glasspool R, Pfisterer J, Phaëton R, Anderson CK, Rodrigues M, Gaba L, Bakirtzi E, Fauci JM, Kalbacher E, Musa FB, Gorman S, Duska LR, Gladieff L, Braly P, Joly F, Thomes Pepin J, Ray-Coquard I, Moore KN. Hardy-Bessard AC, et al. Among authors: gladieff l. Ann Oncol. 2025 Dec;36(12):1503-1513. doi: 10.1016/j.annonc.2025.05.009. Epub 2025 Jun 2. Ann Oncol. 2025. PMID: 40461381 Free article. Clinical Trial.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Pujade-Lauraine E, et al. Among authors: gladieff l. Ann Oncol. 2023 Dec;34(12):1152-1164. doi: 10.1016/j.annonc.2023.09.3110. Epub 2023 Oct 4. Ann Oncol. 2023. PMID: 37797734 Free article. Clinical Trial.
[Cervical cancer: Guidelines for clinical practice].
Carcopino X, Ouldamer L, Huchon C, Asseeva P, Azaïs H, Bendifallah S, Brun JL, Canlorbe G, Chargari C, Chauvet P, Cordoba A, Courcier H, Dabi Y, de Berti M, Diguisto C, Gaillard T, Gauthier T, Gertych W, Gladieff L, Graesslin O, Kerbage Y, Koskas M, Laas E, Lacorre A, Lavoué V, Lecointre L, Lecuru F, Margueritte F, Martinez A, Maternowski PJ, Mathevet P, Menouer I, Mimoun C, Moureau A, Netter A, Philip CA, Rousset P, Sanson C, Thomassin I, Touboul C, Levêque J. Carcopino X, et al. Among authors: gladieff l. Gynecol Obstet Fertil Senol. 2025 Sep;53(9):365-489. doi: 10.1016/j.gofs.2025.07.005. Epub 2025 Jul 17. Gynecol Obstet Fertil Senol. 2025. PMID: 40683521 Free article. French.
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.
Joly F, Leary A, Ray-Coquard I, Asselain B, Rodrigues M, Gladieff L, Meynard G, Abadie-Lacourtoisie S, Lebreton C, Bengrine Lefevre L, Fournel P, Largillier R, Selle F, Frenel JS, Fernandez Diez Y, Foa C, Follana P, Meunier J, Fabbro M, Hardy Bessard AC, Cojean-Zelek I, Kaczmarek E, Bonnet E, Arnaud A, Roche S, Leroy K, Just PA, Leman R, Jeanne C, Callens C, You B, Alexandre J. Joly F, et al. Among authors: gladieff l. Nat Commun. 2025 Aug 26;16(1):7950. doi: 10.1038/s41467-025-62678-x. Nat Commun. 2025. PMID: 40858558 Free PMC article. Clinical Trial.
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.
Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frénel JS, Costaz H, Lebreton C, Pomel C, Colombo PE, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R. Rippstein N, et al. Among authors: gladieff l. Oncologist. 2025 May 8;30(5):oyaf075. doi: 10.1093/oncolo/oyaf075. Oncologist. 2025. PMID: 40349134 Free PMC article.
[Practical management of PARP inhibitors: A French DELPHI consensus].
Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A. Selle F, et al. Among authors: gladieff l. Bull Cancer. 2022 Dec;109(12):1245-1261. doi: 10.1016/j.bulcan.2022.06.011. Epub 2022 Sep 13. Bull Cancer. 2022. PMID: 36109248 Free article. French.
37 results